Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Papillary Craniopharyngiomas
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically proven papillary craniopharyngioma as documented by central pathology review with positive BRAF V600E mutation by IHC.

You may not be eligible for this study if the following are true:

  • 1) Prior treatment with BRAF or MEK inhibitors. 2) Evidence of active bleeding, bleeding diathesis, or hemoptysis (= ½ teaspoon of red blood) = 8 weeks prior to registration.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.